期刊
ACR OPEN RHEUMATOLOGY
卷 4, 期 8, 页码 689-699出版社
WILEY
DOI: 10.1002/acr2.11466
关键词
-
类别
资金
- Wellcome Trust [204825/Z/16/Z]
- National Institute for Health and Care Research (NIHR) [DRF-2014-07-155]
- NIHR [CS-2013-13-032]
- NIHR Leeds Biomedical Research Centre
- National Institutes of Health Research (NIHR) [DRF-2014-07-155] Funding Source: National Institutes of Health Research (NIHR)
This study assessed the outcomes of rituximab treatment in primary Sjogren's syndrome and identified predictors of sustained clinical response. The results suggest that combining immunosuppressants with rituximab and aiming for complete B-cell depletion can increase the odds of response. The study highlights the importance of personalized treatment approaches in improving clinical outcomes in this condition.
Objective To assess outcomes of repeat rituximab cycles and identify predictors of sustained clinical response in systemic manifestations of primary Sjogren syndrome (pSS). Methods An observational study was conducted in 40 rituximab-treated patients with pSS. Clinical response was defined as a 3-point or more reduction in the European League Against Rheumatism (EULAR) Sjogren Disease Activity Index (ESSDAI) at 6 months from baseline. Peripheral blood B cells were measured using highly sensitive flow cytometry. Predictors of sustained response (within two rituximab cycles) were analyzed using penalized logistic regression. Results Thirty-eight out of 40 patients had moderate to severe systemic disease (ESSDAI >5). Main domains were articular (73%), mucocutaneous (23%), hematological (20%), and nervous system (18%). Twenty-eight out of 40 (70%) patients were on concomitant immunosuppressants. One hundred sixty-nine rituximab cycles were administered with a total follow-up of 165 patient-years. In cycle 1 (C1), 29/40 (73%) achieved ESSDAI response. Of C1 responders, 23/29 received retreatment on clinical relapse, and 15/23 (65%) responded. Of the 8/23 patients who lost response, these were due to secondary non-depletion and non-response (2NDNR; 4/23 [17%] as we previously observed in systemic lupus erythematosus with antirituximab antibodies, inefficacy = 2/23, and other side effects = 2/23). Within two cycles, 13/40 (33%) discontinued therapy. In multivariable analysis, concomitant immunosuppressant (odds ratio 7.16 [95% confidence interval: 1.37-37.35]) and achieving complete B-cell depletion (9.78 [1.32-72.25]) in C1 increased odds of response to rituximab. At 5 years, 57% of patients continued on rituximab. Conclusion Our data suggest that patients with pSS should be co-prescribed immunosuppressant with rituximab, and treatment should aim to achieve complete depletion. About one in six patients develop 2NDNR in repeat cycles. Humanized or type 2 anti-CD20 antibodies may improve clinical response in extra-glandular pSS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据